Jubliant Life Sciences has soared 13% to Rs 201 today, extending its two days 9% rally, after its subsidiary, Jubilant Biosys received a milestone payment from AstraZeneca for its research on pain management in the neuroscience therapeutic area.
"The collaboration, which initiated two years ago in neuroscience therapeutic area, has now expanded to cardiovascular and metabolic diseases and focuses on the delivery of a steady stream of pre-clinical outcomes to AstraZeneca by Jubilant," the company said in a press release.
The stock opened at Rs 181 and touched a high of Rs 204 on the NSE. As many as 1.04 million shares have changed hands till 1155 hours, as against an average around 167,496 shares that were traded daily in past two weeks.
